Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting a specific share transaction.
Material Changes
The filing reports an increase in the notional interest in GSK Ordinary Shares held by Ms. E. Walmsley, CEO of GSK Consumer Healthcare. The transaction occurred on July 14, 2016, involving the re-investment of dividends paid on shares held in the Company's 2009 Deferred Annual Bonus Plan.
Transaction Details
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Price: £16.285 per share.
- Total Volume: 1,263.154 shares.
- Composition: The volume includes both personal contributions and matching shares.
Outlook and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total shareholding of Ms. E. Walmsley following this transaction to assess insider confidence.
- Confirm the terms of the 2009 Deferred Annual Bonus Plan regarding dividend re-investment and matching share allocations.
- Note that this filing contains no operational or financial performance data for the period.